tradingkey.logo

TD Cowen lifts McKesson PT to Street-high after drug distributor raises forecast

ReutersSep 24, 2025 11:10 AM

TD Cowen raised drug distributor McKesson's MCK.N PT from $830 to a Street-high of $864

New PT represents an 16.5% upside to the stock's last close

Brokerage sees upside for MCK, citing a stronger outlook for North America pharma and oncology/multispecialty and the lift to long‑term adjusted EPS targets

TD Cowen says that since biosimilar interchangeability is not currently factored into MCK's guide it presents substantial upside

Biosimilar interchangeability means a copy of a biologic medicine can be swapped in at the pharmacy for the original without the doctor needing to change the prescription, because it's proven to work the same and be just as safe

At least six brokerages raised their PT after MCK raised its annual profit forecast on Tuesday

As of last close, MCK stock was up ~31% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI